Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet by Sodhi, Komal et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
6-2015
Fructose Mediated Non-Alcoholic Fatty Liver Is
Attenuated by HO-1-SIRT1 Module in Murine
Hepatocytes and Mice Fed a High Fructose Diet
Komal Sodhi
Marshall University, sodhi@marshall.edu
Nitin Puri
Gaia Favero
Sarah Stevens
Marshall University, stevens107@marshall.edu
Charles Meadows
Marshall University, cmeadows@marshall.edu
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Sodhi K, Puri N, Favero G, Stevens S, Meadows C, Abraham NG, Rezzani R, Ansinelli H, Lebovics E, Shapiro JI. Fructose Mediated
Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet. PLoS
ONE. 2015;10(6):e0128648.
Authors
Komal Sodhi, Nitin Puri, Gaia Favero, Sarah Stevens, Charles Meadows, Nader G. Abraham, Rita Rezzani,
Hayden A. Ansinelli, Edward Lebovics, and Joseph I. Shapiro
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_bm/150
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Abstract
Background
Oxidative stress underlies the etiopathogenesis of nonalcoholic fatty liver disease (NAFLD),
obesity and cardiovascular disease (CVD). Heme Oxygenase-1 (HO-1) is a potent endoge-
nous antioxidant gene that plays a key role in decreasing oxidative stress. Sirtuin1 (SIRT1)
belongs to the family of NAD-dependent de-acyetylases and is modulated by cellular redox.
Hypothesis
We hypothesize that fructose-induced obesity creates an inflammatory and oxidative envi-
ronment conducive to the development of NAFLD and metabolic syndrome. The aim of this
study is to determine whether HO-1 acts through SIRT1 to form a functional module within
hepatocytes to attenuate steatohepatitis, hepatic fibrosis and cardiovascular dysfunction.
Methods and Results
We examined the effect of fructose, on hepatocyte lipid accumulation and fibrosis in murine
hepatocytes and in mice fed a high fructose diet in the presence and absence of CoPP, an
inducer of HO-1, and SnMP, an inhibitor of HO activity. Fructose increased oxidative stress
markers and decreased HO-1 and SIRT1 levels in hepatocytes (p<0.05). Further fructose
supplementation increased FAS, PPARα, pAMPK and triglycerides levels; CoPP negated
this increase. Concurrent treatment with CoPP and SIRT1 siRNA in hepatocytes increased
FAS, PPARα, pAMPK and triglycerides levels suggesting that HO-1 is upstream of SIRT1
and suppression of SIRT1 attenuates the beneficial effects of HO-1. A high fructose diet
increased insulin resistance, blood pressure, markers of oxidative stress and lipogenesis
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along with fibrotic markers in mice (p<0.05). Increased levels of HO-1 increased SIRT1 lev-
els and ameliorated fructose-mediated lipid accumulation and fibrosis in liver along with
decreasing vascular dysfunction (p<0.05 vs. fructose). These beneficial effects of CoPP
were reversed by SnMP.
Conclusion
Taken together, our study demonstrates, for the first time, that HO-1 induction attenuates
fructose-induced hepatic lipid deposition, prevents the development of hepatic fibrosis and
abates NAFLD-associated vascular dysfunction; effects that are mediated by activation of
SIRT1 gene expression.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is deposition of excess fat in hepatocytes that is not
associated with alcoholism. Prevalence of NAFLD, and associated steatohepatitis, is steadily
increasing in developed countries. In the United States, prevalence of NAFLD has been
reported to be between 10 and 46% with NASH (biopsy-based) occurring in 3–5% of the popu-
lation [1,2]. The impact of NAFLD diagnostic criteria on reported prevalence is evident in the
National Health and Nutrition Examination Surveys (NHANES). NHANES 1988–1994
reported prevalence of NAFLD at 5.5%, NHANES 1999–2004 9.8%, and NHANES2005-2008
11%. These were based on elevated serum aminotransferases. A reevaluation of NHANES
1988–1994 based on hepatic steatosis on ultrasound and the absence of excessive alcohol con-
sumption found the prevalence to actually be 19% [3].
NALFD encompasses a continuum of histological findings ranging from steatosis alone to
nonalcoholic steatohepatitis (NASH), inflammation, and fibrosis [4–6]. Both non-alcoholic
fatty liver (NAFL) and NASH are manifestations of metabolic imbalance and are characterized
by elevated hepatic adiposity, insulin resistance, increased free fatty acid (FFA) levels, and
increased inflammatory mediators [7–9]. Up to 30% of patients with NAFLD are at risk of pro-
gression to steatohepatitis with inflammatory infiltration and eventually, fibrosis [10]. Most of
these patients have normal liver function on routine labs [11], suggesting that the true preva-
lence may be even higher. Importantly, there is mounting evidence that NAFLD is a risk factor
in patients at high CVD risk [12, 13]. NAFLD contributes to the progression of early athero-
sclerosis and endothelial dysfunction independently of traditional CVD risk factors [14, 15].
Dietary sugars, particularly fructose, contribute to chronic metabolic imbalance and to the
development of NAFLD. Increased Reactive oxygen species (ROS) and lipid peroxidation are
major contributors to the proposed second-hit mechanism of NAFLD [16]. In this regard,
high-fructose (HFr) diet promotes de novo lipogenesis with intrahepatic lipid accumulation,
triglyceride formation, hepatic insulin resistance, and hyperglycemia [17–24]. Additionally,
HFr precipitates oxidative stress and this bolsters the suspected link between fructose intake
and NAFLD [25]. ROS are major contributors to the liver damage of NAFLD and are involved
in the development of hepatic fibrosis. This includes proliferation of the hepatic stellate cells
(HSC) with increased collagen synthesis [26]. HSCs activation is regulated by cytokines and
ROS released by damaged hepatocytes [27, 28]. Therefore, suppression of oxidative stress and
inhibition of HSC activation could provide a therapeutic alternative in the treatment of liver
fibrosis.
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SIRT1 is a class III protein deacetylase, a crucial cellular survival protein in combating meta-
bolic imbalance [29]. It regulates glucose and lipid metabolism through its deacetylase activity
and via its direct and indirect involvement in insulin signaling. Activation of SIRT1 decreases
fatty liver by a reducing expression of lipogenic enzymes [30]. Hepatocyte specific loss of
SIRT1 caused peroxisome proliferator-activated receptor α (PPARα) signal failure and
decrease in fatty acid β-oxidation [31]. Liver-specific SIRT1 deficiency caused hepatic glucose
overproduction, chronic hyperglycemia and increased ROS production. Importantly, SIRT1 is
amenable to redox manipulations and is suppressed by ROS [32]. Other investigators, includ-
ing our lab, have shown SIRT1 rescue by antioxidants in a variety of tissues under oxidative
stress. In this regard, the heme-heme oxygenase system (HO) is one of the key cellular-antioxi-
dant defenses that lowers ROS by the breakdown of heme (pro-oxidant) to carbon monoxide
(CO) and biliverdin (BV). BV is rapidly reduced to the antioxidant, bilirubin [33, 34]. There
are two HO isoforms: the constitutive, Heme-Oxygenase isoenzyme 2 (HO-2); and, the induc-
ible, HO-1. HO-1 is up-regulated during alterations in cellular redox and plays a role in myriad
of pathological conditions, including metabolic syndrome [35]. Increasing HO activity results
in the reversal of oxidative stress and a decrease in liver damage (reviewed in [36]). Increased
HO-1 levels increase the phosphorylation of AMP-activated protein kinase (AMPK), and
decrease fatty acid synthase (FAS) resulting in an increase in insulin sensitivity and the lower-
ing of fatty acid levels [37, 38]. Also, we have recently shown that induction of HO-1 attenuated
the development of fatty liver and decreased lipid droplet size in obese mice [39], thus substan-
tiating a significant role of HO-1 against heme-mediated adiposity and fatty liver. For this
study we have hypothesized that HO-1, a critical anti-oxidant, forms a cytoprotective module
with SIRT1 and together, they counteract diet-activated pathways in the liver that lead to
NAFLD and NASH.
For this study we have hypothesized that HO-1, a critical anti-oxidant, forms a cytoprotec-
tive module with SIRT1 and together, they counteract diet-activated pathways in the liver that
lead to NAFLD. The aim of the study is to demonstrate that HO-1 induction in the liver
reduces diet-induced metabolic imbalance, ROS, insulin resistance, and hepatic lipid deposi-
tion and also prevent the development of hepatic fibrosis; effects that are mediated by activa-
tion of SIRT1 gene expression. We believe that understanding the interactions between HO-1
and SIRT1 in NAFLD and related hepatic fibrosis will lead to the development of new bio-
markers and therapeutic strategies to fight hepatic dysfunction. This will result in improved
quality of life and life expectancy in the obese, insulin resistant patient.
Material and Methods
Experimental design for in vitro experiment
Frozen mouse hepatocytes (AML12, CRL-2254) were purchased from ATTC. For experiments
they were cultured in DMEM and Ham's F12 medium with supplements. Cells were plated in
12-well dishes and 75-cm2 flasks at a density of 1-2X104 cells and were treated every alternate
day for 5 days with and without fructose (500 μM) in the absence and presence of CoPP
(5μM), small interfering RNA (siRNA) for SIRT1 (or non-specific siRNA), and SnMP (5μM)
and in cells over-expressing SIRT1. Commercially available (Ambion Silencer Select) siRNA
and an appropriate scrambled RNA for SIRT1 was employed for “knockdown” studies. For
over-expression studies we employed mouse SIRT1, full-length variant (isoform 1, Gene ID-
93759) synthesized into pJ603 vector along with corresponding pJ603-GFP negative control,
by DNA 2.0 Inc. Transfection of cells was achieved using FuGENE HD transfection reagent as
described previously [29].
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Experimental design for in vivo experiment
All animal studies were approved by the Marshall University Animal Care and Use Committee
in accordance with the National Institutes of Health Guidelines for Care and Use of Laboratory
Animals. Forty, eight week–old C57Bl6 male mice were used in the studies. Mice were fed a
HFr diet for 8 weeks, a time frame in which the manifestations of fatty liver are present, and
were divided into four groups: 1) control diet; 2) HFr diet; 3) HFr diet treated for the last 4
weeks with Cobalt Protoporphyrin (CoPP) (5 mg/kg, twice a week); and 4) HFr diet treated
for the last 4 weeks with CoPP (5 mg/kg, twice a week) and Tin mesoporphyrin (SnMP)
(20mg/kg, twice a week). Control chow (Harlan, Teklad Lab Animal Diets, US) contained kcal
from protein 30%, carbohydrate 57% and fat 13%. HFr diet (Harlan, Teklad Lab Animal Diets,
US) contained kcal from protein 20.2%, carbohydrate 66.8% and fat 12.9%. Fat content of the
two diets is similar (both derived from porcine). The control diet fat composition includes
cholesterol ppm 209, Linoleic acid 1.05%, Linolenic acid 0.09%, Arachidonic acid 0.02%,
Omega-3-Fatty Acid 0.3%, Total Saturated Fatty Acids 1.48% and Total Unsaturated Fatty
Acids 1.62%. The HFr diet fat composition includes cholesterol ppm 950, Linoleic acid 0.59%,
Linolenic acid 0.04%, Arachidonic acid 0.01%, Omega-3-Fatty Acid 0.05%, Total Saturated
Fatty Acids 1.91% and Total Unsaturated Fatty Acids 1.75%. HFr diet is in accordance with
published reports using similar diets to induce hepatic steatosis and steatohepatitis. Mice were
weighed every week and blood pressure determined by the tail cuff method every 4 weeks dur-
ing the course of the experiment. Prior to the experiment, mice were all acclimated to the tail
cuff method. Mice were placed in a heat-controlled box (36–38°C) for approximately 10 mins
before applying the tail cuff. The mean of a minimum of 5 measurements was obtained from
each mouse. All measurements were determined at the same time of day for all mice. At the
end of the 8-week period, mice were placed on an 8-hour fast, anesthetized with sodium pento-
barbital (65 mg/kg, i.p.) and blood was obtained from the tail vein for measurement of glucose
using a glucometer (Lifescan Inc., Miligitas, CA) and measurement of insulin using ELISA
assay kit (Abcam, Cambridge, MA). Blood samples were collected in K3EDTA tubes at sacrifice
and the plasma was separated. Alanine Aminotransferase (ALT) was measured in mice plasma
to study liver function test. Liver and aorta tissues were flash frozen in liquid nitrogen and
maintained at -80°C until assayed.
A second experiment was done in which mice were placed on a HFr diet for 20 weeks in
order to study the prolonged effect of a HFr diet on the progression of hepatic fibrosis. The
choice of time was predicated upon previous studies in mice that have shown hepatic fibrosis is
clearly evident after 16–20 weeks of a HFr diet. Mice were divided into four groups: 1) control
diet; 2) HFr diet; 3) HFr diet treated for the last 4 weeks with CoPP (5 mg/kg, twice a week);
and 4) HFr diet treated for the last 4 weeks with CoPP (5 mg/kg, twice a week) and SnMP
(20mg/kg, twice a week). After 20 weeks, liver tissue was flash frozen in liquid nitrogen and
maintained at -80°C until assayed.
Measurement of Isoprostane, Heme, and Cytokine Levels
Isoprostane levels were determined in conditioned media and in mouse serum using an ELISA
assay (Cayman Chemical; Ann Arbor, MI). Heme content in murine hepatocytes was deter-
mined by the pyridine hemochromogen method as described previously [40, 41]. The absor-
bance difference between λ 557 and λ 530 nm was used to calculate heme using an extinction
coefficient of 20.7mM-1cm-1. Tissue necrosis factor α (TNFα) was determined in mouse serum
using an ELISA assay according to the manufacture’s protocol (Pierce Biotechnology, Woburn,
MA).
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Measurement of Superoxide Levels for in vitro experiment
Hepatocytes were cultured on 96-well plates until they achieved approximately 70% conflu-
ence. After treatment with or without fructose (500 μM) in the absence and presence of CoPP
(5μM) and SnMP (5μM) for 2 days, the cells were incubated with 10 μM dihydroethidium
(DHE) for 30 min at 37°C. Fluorescence intensity was measured using a Perkin-Elmer Lumi-
nescence Spectrometer at excitation/emission filters of 530/620 nm.
Measurement of Triglyceride Levels for in vitro experiment
Hepatocytes were cultured in 75-cm2 flasks until they achieved approximately 70% confluence.
After treatment for 5 days with or without fructose (500 μM) in the absence and presence of
CoPP (5μM) and SnMP (5μM), the cells were collected and washed in ice-cold phosphate-buff-
ered saline (PBS). Triglyceride levels were determined in hepatocytes using a commercially
available kit (Abcam, Cambridge, MA).
Determination of homeostasis model assessment of insulin resistance
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from mice
blood using glucose and insulin concentrations obtained after 8 h of food withdrawal, using the
following formula: HOMA-IR = [fasting insulin (μU/ mL) × fasting glucose (mmol/L)] / 22.5.
Determination of Triglyceride, Cholesterol content in hepatic tissue
Liver samples were homogenized in ice-cold PBS. Tissue lipids were extracted with methanol/
chloroform (1:2), dried, and resuspended in 5% fat-free bovine serum albumin. Triglyceride
and Cholesterol levels were determined using a commercially available kit according to the
manufacture’s protocol (Abcam, Cambridge, MA).
Determination of Free Fatty Acids levels in hepatic tissue
Liver tissue (10mg) was homogenized in 1% (w/v) Triton X-100 in chloroform solution. After
centrifugation of samples, the lower organic phase was collected and dried to remove chloro-
form. The dried lipids were dissolved in Fatty acid assay buffer and FFA levels were determined
using a commercially available kit according to the manufacture’s protocol (Sigma-Aldrich,
St. Louis, MO).
Liver Oil Red-O staining
Frozen liver tissue sections (6 μm thick) were stained with NovaUltra Oil Red O Stain Kit (IHC
World, LLC, Woodstock, MD, USA) according to the protocol provided by manufacturer.
Liver tissue microphotographs were taken on a Nikon Eclipse 80i microscope equipped with a
Nikon camera head DS-Fi1 (Nikon, Japan). For quantitative analysis, two or three random
field/slide was taken from three liver samples from each group at magnification of 40x. The
total area of red pixels on the Oil-Red-O stained tissue section was measured by using the
Image J software provided by NIH. The data were expressed as mean±SEM of percentage of
the Oil-Red-O stained areas with respect to total area.
Immunohistochemistry for in vivo experiments
Immunohistochemistry was done on the liver samples obtained from mice treated with HFr
diet for 20 weeks as described above. Sections were stained with Masson’s-trichrome for
Role of HO-1-SIRT1 Axis in NAFLD
PLOSONE | DOI:10.1371/journal.pone.0128648 June 22, 2015 5 / 22
conventional light microscopy to examine fibrosis and collagen accumulation in hepatic tis-
sues. The stained sections were examined by microscope (Olympus, Japan).
RNA extraction and real-time PCR for in vitro and in vivo experiments
Total RNA was extracted from murine hepatocytes and mice liver tissue using RNeasy Protect
Mini kit (QIAGEN, Maryland, USA) according to manufacturer’s instructions. Total RNA
(1μg) was transcribed into cDNA using GeneAmp kit (Applied Biosystems, Branchburg, NJ,
USA) reverse transcription reagents. Total RNA was analyzed by a quantitative real time poly-
merase chain reaction (qRT-PCR). Real-time PCR was performed using SYBR Green PCR
Master Mix (Applied Biosystems) on a 7500 HT Fast Real-Time PCR System (Applied Biosys-
tems). Specific primers used were HO-1, PPARα, FAS, SIRT1, ACC, Srebp-1c, Elvol6, SCD-1
and actin. Each reaction was performed in triplicate. The comparative threshold cycle (Ct)
method was used to calculate the fold amplification as specified by the manufacturer. Appropi-
ate positive and negative controls for siRNAs were used for the experiments. All experimental
samples were normalized using actin as an internal control and normalization was performed
in separate reactions.
Western blot analysis
Murine hepatocytes pellets, liver and aortic tissue were pulverized under liquid nitrogen and
placed in a homogenization buffer comprising (mmol/l): 10 phosphate buffer, 250 sucrose, 1
EDTA, 0.1 PMSF and 0.1% v/v tergitol, pH 7.5. Homogenates were centrifuged at 27,000xg for
10 minutes at 4°C. The supernatant was isolated and protein levels were assayed (Bradford
Method) and immunoblotting was performed as described previously [29, 42, 43]. The super-
natant was used for the determination of HO-1, SIRT1, Insulin receptor-β, IR Tyr 1146, pAKT
(ser473), AKT, G6Pase, FAS, aP2, TGF β, MMP2, gp phox91, peNOS, iNOS, pAMPK and
AMPK. β Actin was used to ensure adequate sample loading for all Western blots.
Statistical analyses
Statistical significance was determined using one-way analysis of variance followed by Tukey-
Kramer post hoc test. P<0.05 was considered to be significant. Data are expressed as
means ± S.E.M.
Results
High-fructose treatment increases oxidative stress markers and
decreases expression of HO-1 and SIRT1 in cultured murine
hepatocytes; induction of HO-1 reverses these effects
In accordance with our hypothesis our results showed that cultured murine hepatocytes treated
with HFr increased isoprostane levels obtained from conditioned media as compared to the
control. CoPP decreased isoprostane levels (p<0.05) (Fig 1A) and concurrent treatment with
SnMP reversed the beneficial effects of CoPP. Similarly heme and superoxide levels were
increased in murine hepatocytes treated with HFr as compared to the control. CoPP decreased
heme and superoxide levels as compared to HFr treatment (Fig 1B and 1C respectively,
p<0.05) and concurrent treatment with SnMP reversed the beneficial effects of CoPP, indicat-
ing that HO activity is required for the reduction in these oxidative markers.
Hepatocytes treated with HFr displayed a marked decrease in HO-1 levels as compared to
the control (Fig 1D, p<0.05). CoPP increased HO-1 levels and SnMP also increased HO-1
expression. However, these findings are not surprising as SnMP, which induced a significant
Role of HO-1-SIRT1 Axis in NAFLD
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increase in HO-1 expression, is a potent inhibitor of HO activity, as shown previously [35, 42,
43]. SIRT1 expression was decreased in hepatocytes treated with fructose while induction of
HO-1, via CoPP, rescued SIRT1 and increased the expression of SIRT1 significantly as com-
pared to cells treated with fructose. Furthermore, SnMP reversed the beneficial effect of CoPP
and decreased the expression of SIRT1 (Fig 1E, p<0.01).
Potent antioxidants Biliverdin and tempol, rescues SIRT1 expression
As per our central hypothesis, HO-1 rescues cellular SIRT1 expression primarily via its antioxi-
dant effects. To establish the “proof of concept” for this central hypothesis, we treated the hepa-
tocytes with other antioxidants (antioxidant product of the HO system, BV and SOD-mimetic,
tempol) in presence of fructose and studied the expression of SIRT1 gene. As expected our
results showed that hepatocytes treated with fructose decreased SIRT1 expression (Fig 1F).
Importantly, BV, (10 μM concentration) and tempol (100 μM), potent antioxidants, rescued
SIRT1 from fructose induced oxidative stress (Fig 1F; p<0.01). These results support our
Fig 1. Effect of high-fructose (HFr) supplementation (500 μM) onmarkers of oxidative stress and HO-1 and SIRT1 gene expressions in hepatocytes
treated with and without CoPP (5 μM) and SnMP (5 μM). (A) Isoprostanes level in condition media of hepatocytes (B) heme content measurement in
hepatocytes (C) superoxide measurement in hepatocytes. (D) HO-1 mRNA levels (E) SIRT-1 protein levels. (F) Effect of Biliverdin and Tempol on SIRT1
expression in fructose (Fr)-treated hepatocytes. Hepatocytes were treated with biliverdin (10 μM) and with Tempol (100 μM) in presence of fructose (500 μM)
for 24 hours. Results are mean±SE, n = 6/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g001
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notion that hepatocyte HO-1-induction will restore cellular redox balance, which is impaired
in NAFLD and will increase cellular SIRT1 expression.
HO-1 induction increases pAMPK and PPARα and decreases FAS
levels in cultured murine hepatocytes; SIRT-1 knockdown decreases
pAMPK and PPARα and increases FAS levels
To assess whether HO-1 requires the participation of SIRT1 to mediate and/or amplify its
actions, we studied the effect of SIRT1 siRNA and SIRT plasmid in hepatocytes treated with
fructose. Our results showed that fructose decreased pAMPK and PPARα levels and increased
the expression of FAS (Fig 2A, 2B and 2C respectively); this effect of fructose treatment was
negated by treatment with CoPP. Interestingly, concurrent treatment with CoPP and SIRT1
siRNA decreased pAMPK and PPARα and increased FAS levels suggesting that HO-1 is
upstream of SIRT1 and that suppression of SIRT1 attenuates the beneficial effects of increased
levels of HO-1. We also utilized plasmid SIRT1 to assess if increased expression of SIRT1 (in
the absence of HO-1 up-regulation) is sufficient to prevent the detrimental effects of HFr on
lipid accumulation and metabolic imbalance. Treatment of hepatocytes with fructose, SnMP
and SIRT plasmid decreased pAMPK and PPARα and increased FAS levels as compared to
Fig 2. Effect of CoPPwith and without SIRT1-siRNA, and with and without SIRT plasmid on pAMPK, PPARα, FAS expression and triglyceride
levels in fructose (Fr)-treated hepatocytes. (A) pAMPK/AMPK expression by western blot analysis. (B) PPARαmRNA levels. (C) FASmRNA levels
measured by RT-PCR in hepatocytes. Results are mean±SE, n = 4/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP, $ vs Fr+CoPP+SIRT
Plasmid. (D) Triglyceride levels measured by RT-PCR in hepatocytes. Results are mean±SE, n = 4/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs
HFr+CoPP, $ vs Fr+CoPP+SIRT Plasmid.
doi:10.1371/journal.pone.0128648.g002
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hepatocytes treated with fructose, CoPP and SIRT plasmid (Fig 2A, 2B and 2C respectively;
p<0.05). In agreement with our hypothesis, our results further showed that hepatocytes treated
with fructose, CoPP and SIRT plasmid did not significantly decrease pAMPK, PPARα and
FAS levels as compared to cells treated with fructose and CoPP alone indicating a HO-1 depen-
dent activation of SIRT1 expression.
HO-1 induction decreases triglycerides levels in cultured murine
hepatocytes; SIRT-1 knockdown attenuates the inhibitory action and
increases triglycerides levels
As seen in Fig 2D, fructose increased triglycerides content in hepatocytes; this increase was
negated by treatment with CoPP. Concurrent treatment with CoPP and SIRT1 siRNA
increased triglycerides levels further suggesting that HO-1 is upstream of SIRT1. Treatment of
hepatocytes with fructose, SnMP and SIRT plasmid increased triglycerides levels as compared
to hepatocytes treated with fructose, CoPP and SIRT plasmid (Fig 2D; p<0.05). Our results
further showed that hepatocytes treated with fructose, CoPP and SIRT plasmid did not signifi-
cantly decrease triglycerides levels as compared to cells treated with fructose and CoPP alone
indicating a HO-1 dependent activation of SIRT1 expression.
Effect of HO-1 induction on metabolic profile and liver function in mice
fed a high-fructose diet
A HFr diet increased blood pressure in mice compared to their control group, (p<0.05) (Fig
3A), an effect reversed via CoPP. Similarly our results showed that fasting blood glucose levels
were increased in mice fed a HFr diet as compared to the control (Fig 3B; p<0.05). CoPP
decreased blood glucose levels and concurrent treatment with SnMP reversed the beneficial
effects of CoPP. Correspondingly, HOMA-IR was increased in mice fed a HFr diet as com-
pared to the control mice (Fig 3C; p<0.05). CoPP significantly decreased HOMA-IR as com-
pared to mice fed a HFr diet. Further ALT levels were significantly increased in mice fed HFr
diet (Fig 3D) as compared to the control group and this increase was negated by treatment
with CoPP. Furthermore, SnMP reversed the beneficial effect of CoPP and decreased ALT lev-
els in plasma (p<0.01).
Effect of HO-1 induction on hepatic lipid content in mice fed a high-
fructose diet
To examine whether HO-1 induction can suppress the formation of hepatic steatosis, the levels
of triglycerides and cholesterol in hepatic tissue were measured. Our results showed that tri-
glycerides and cholesterol content (Fig 3E and 3F respectively; p<0.05) was significantly
increased in mice fed a HFr diet as compared to control mice. As expected, CoPP decreased tri-
glycerides and cholesterol content as compared to mice fed a HFr diet and concurrent treat-
ment with SnMP reversed the beneficial effects of CoPP.
Effect of HO-1 induction on hepatic lipogenesis and FFA levels in mice
fed a high-fructose diet
As shown in Fig 4A, mice fed a HFr diet have significantly (p<0.05) more lipid accumulation
in liver compared to the mice fed a normal chow diet. Oil red O staining of liver from mice fed
a HFr diet showed that CoPP decreased lipid accumulation. The decrease in lipid accumulation
in mice treated with CoPP was reversed by co-administration of SnMP (Fig 4A). Further our
results showed that hepatic FFA levels were significantly increased in mice fed a HFr diet as
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compared to the control mice. CoPP decreased FFA levels in hepatic tissue as compared to
mice fed a fructose diet (Fig 4B; p<0.05). Expression of genes involved in hepatic fatty acid
synthesis; Elvol6 and Srebp-1c were induced in mice fed with a high-fructose diet compared to
control group. Administration of CoPP significantly reduced the increased mRNA expressions
to near control levels (Fig 4C). Similarly, ACC and SCD-1 mRNA expressions were signifi-
cantly increased in mice fed a HFr diet as compared to the control mice and this increase was
negated by treatment with CoPP (Fig 4D). Furthermore, SnMP reversed the beneficial effect of
CoPP and decreased ACC and SCD-1 levels in hepatic tissue (p<0.01).
Fig 3. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) onmetabolic profile and hepatic lipid content in mice fed a high fructose diet
for 8 weeks. (A) Blood pressure. (B) Fasting blood glucose levels. (C) HOMA-IR (D) Plasma ALT levels. (E) Triglycerides levels in hepatic tissue. (F)
Cholesterol levels in hepatic tissue. Results are mean±SE, n = 6/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g003
Fig 4. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) in mice fed a high fructose diet for 8 weeks on hepatic lipogenesis and FFA
levels. (A) Oil Red O staining of lipids in liver and quantitative analysis of different groups, magnifications: 40X (n = 4). A representative section for each
group is shown; (B) Hepatic FFA levels. (C) Elvol6 and Srebp-1c mRNA levels measured by RT-PCR and (D) ACC and SCD-1 mRNA expressions measured
by RT-PCR. Results are mean±SE, n = 6/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g004
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Effect of HO-1 induction on hepatic SIRT1 expression and markers of
oxidative stress in mice fed a high-fructose diet
Mice fed a HFr diet and concurrently treated with CoPP exhibited increased hepatic HO-1
expression as compared to the control (Fig 5A). SnMP also increased HO-1 expression. How-
ever, these findings are not surprising as SnMP, which induced a significant increase in HO-1
expression, remains a potent inhibitor of HO activity, as shown previously [35, 42, 43]. Mice
fed a HFr diet exhibited decreased hepatic SIRT1 expression as compared to the control (Fig
5B). Furthermore, SnMP reversed the beneficial effect of CoPP and decreased the expression of
SIRT1 (p<0.05). Mice fed a HFr diet had increased plasma isoprostane levels and an increased
expression of the hepatic NADPH-oxidase-subcomponent, gp/phox91 (Fig 5C and 5D respec-
tively; p<0.05), a potent marker of oxidative stress, compared to the control mice. CoPP
reduced isoprostane and gpphox 91 levels as compared to mice fed a fructose diet (p<0.05).
SnMP reversed the effect of CoPP and increased the markers of oxidative stress.
Fig 5. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) in mice fed a high fructose diet for 8 weeks on HO-1 mRNA, SIRT1mRNA,
plasma isoprostane and gp phox91 protein expression. (A) HO-1 mRNA levels measured by RT-PCR. (B) SIRT1 mRNA levels measured by RT-PCR.
(C) Plasma isoprostane levels and (D) gp phox91 protein expression. Results are mean±SE, n = 6/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs
HFr+CoPP.
doi:10.1371/journal.pone.0128648.g005
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Effect of HO-1 induction on hepatic insulin receptors, pAKT, G6Pase
levels and lipogenic markers in mice fed a high-fructose diet
Western blots analyses of generic insulin receptor-beta (IR-β) (Fig 6A) and insulin receptor
phosphorylated at tyrosine 1466 (Fig 6B) showed a significant decreased expression in mice fed
a HFr diet compared with their controls. This decrease was blocked by the administration of
CoPP while the co-administration of CoPP and SnMP reversed the effect of CoPP. Similarly,
mice fed a HFr diet showed reduced phosphorylation of AKT in liver when compared to con-
trol mice (Fig 6C). CoPP restored the phosphorylation of AKT to levels comparable to control
mice while SnMP reversed the beneficial effects of CoPP on AKT phosphorylation (p<0.05).
Further our results showed that mice fed a HFr diet had higher mRNA expression of
G6Pase, an important marker of gluconeogenesis, in hepatic tissue as compared to the control
mice and this increase was negated by treatment with CoPP (Fig 6D; p<0.05). Also our results
showed that a HFr diet increased expression of lipogenic markers, FAS, (p<0.05) (Fig 6E) and
aP2 (Fig 6F), in hepatic tissue compared to their control group. Further our results indicate
Fig 6. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) in mice fed a high fructose diet for 8 weeks on western blot and densitometry
analysis. (A) insulin receptor-β. (B) Insulin receptor phosphorylated at tyrosine 1146. (C) pAKT/AKT levels. (D) G6Pase. (E) FAS and (F) aP2 expression.
Data are shown as mean band density normalized to β-actin. Results are mean±SE, n = 4/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g006
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that mice treated with CoPP had decreased FAS and aP2 levels in hepatic tissue as compared to
mice fed a HFr diet alone (Fig 6E and 6F respectively; p<0.05). Furthermore, mice treated with
SnMP along with CoPP had increased FAS (p<0.05) and aP2 expression demonstrating the
beneficial effect of the HO-1-SIRT axis.
HO-1 induction attenuates high-fructose diet-induced inflammatory and
fibrotic markers in mice fed a high-fructose diet for 20 weeks
Immunohistochemistry was done on liver samples obtained from mice treated for 20 weeks
with a HFr diet. No fibrosis was observed in the control mice (Fig 7Aa). The mice fed a HFr
diet showed 10% fibrosis (Fig 7Ab). Further our results showed that administration of SnMP to
CoPP treated mice fed a HFr diet reversed the beneficial effect of CoPP and had 9% fibrosis
(Fig 7Ad). Mice fed a HFr diet had a significant increase in TNFα, a potent inducer of collagen
synthesis (Fig 7B) compared to control mice. CoPP reduced TNFα levels as compared to mice
Fig 7. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) on hepatic fibrosis, markers of hepatic fibrosis in mice fed high-fructose diet
for 20 weeks. (A) Masson’s trichrome staining in liver and quantitative analysis of WT, high fructose, high fructose treated with CoPP, and high fructose
treated with CoPP and SnMP, magnifications: 40× (n = 4) (* Indicates fibrosis). A representative section for each group is shown. (B) Plasma TNFα levels.
(C) MMP2 protein expression and (D) TGFβ protein expression on western blot analysis. Data are shown as mean band density normalized to β-actin.
Results are mean±SE, n = 4/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g007
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fed a fructose diet (p<0.05). SnMP abolished the CoPP effect suggesting the HO activity is
required for the beneficial effects of CoPP. Moreover, mice fed a HFr diet showed a significant
increase in MMP-2 and TGF1β expression (Fig 7C and 7D respectively; p<0.05), compared to
the control mice. Treatment with CoPP reduced MMP-2 and TGF1β expression as compared
to mice on a HFr diet (Fig 7C and 7D respectively). Administration of SnMP to CoPP treated
mice fed a HFr diet reversed the beneficial effect of CoPP and increased markers of hepatic
fibrosis.
HO-1 induction attenuates high-fructose diet-induced redox markers in
the aorta
Our results showed activation of inflammatory pathways (iNOS) in the aorta of mice fed a HFr
diet (Fig 8A). CoPP increased the aortic expression of peNOS (Fig 8B; p<0.05); the concurrent
administration of SnMP with CoPP decreased the expression of peNOS. Therefore CoPP
increased NO bioavailability, restoring the balance of aortic eNOS and iNOS isoforms and the
redox state. Further mice fed a HFr diet had a decreased expression of pAMPK (Fig 8C;
Fig 8. Effect of induction of HO-1 (CoPP) and inhibition of HO (SnMP) in mice fed a high fructose diet for 8 weeks on western blot and densitometry
analysis of aortic tissue. (A) iNOS protein expression. (B) peNOS protein expression and (C) pAMPK protein expression. Data are shown as mean band
density normalized to β-actin. Results are mean±SE, n = 4/group. * p<0.05 vs CTR; # p<0.05 vs HFr, + p<0.05 vs HFr+CoPP.
doi:10.1371/journal.pone.0128648.g008
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p<0.05) as compared to the control group. CoPP increased pAMPK levels (p<0.05) as com-
pared to mice fed a fructose diet. SnMP abolished the beneficial effects of CoPP.
The results of the control group treatments are included in tables A to H in supporting
information (S1 File).
Discussion
This study establishes the protective role of the heme-HO system in counteracting pathologies
brought about by a HFr diet, specifically; reduction in hepatic lipid accumulation, improve-
ment in insulin sensitivity and metabolic balance, and attenuation of hepatic fibrosis. Impor-
tantly, our results show that this protection, at least in part, is mediated by the HO-
1-dependent rescue of hepatic SIRT1. We demonstrate that HO-1 acts through SIRT1 to form
a functional module within hepatocytes to attenuate steatohepatitis, hepatic fibrosis and meta-
bolic imbalance. Thus our results allude to the presence of a hepatic HO-1-SIRT1 axis that
attenuates hepatic steatotic pathways and has systemic effects including, improvement of vas-
cular function and restoration of insulin sensitivity.
The first key finding of the study is the redox-dependent attenuation of hepatocyte SIRT1
that is rescued by HO-1. High-sugar diets alter redox state of hepatocytes and eventually cause
increased lipid accumulation in these cells [44, 45]. This is confirmed in our study by elevated
oxidative stress in hepatocytes cultured with high-fructose supplementation. This is accompa-
nied by suppression of hepatocyte SIRT1 levels. ROS-mediated suppression of SIRT1 has been
reported by us and by other investigators [32]; also, the antioxidant properties of the heme-HO
system are well documented [36, 46–49]. Thus, protective effects of HO-1-induction on hepa-
tocyte SIRT1 are novel but not surprising. This is the first report showing hepatic SIRT1 rescue
by the up-regulation of the heme-HO system in hepatocytes stressed by high-fructose supple-
ment. Antioxidant properties of SIRT1 are primarily ascribed to BV, which has the ability to
quench variety of free radicals. Tempol, on the other hand, is a SOD-mimetic and primarily
reduces superoxide levels. SIRT1 rescue by both, biliverdin and tempol, lead us to propose that
increased superoxide levels could bring about high-fructose mediated SIRT1 suppression.
However, it is important to point out that the precise molecular mechanisms of this antioxi-
dant-rescue of SIRT1 are not fully understood.
As expected, a HFr diet precipitated not only oxidative stress but also fatty changes in the
hepatocytes. HFr treatment is a well-established model that emulates fatty changes in hepatocytes
both, in vivo and in vitro [22, 50–53]. Activation of the lipogenic genes, including FAS, is a key
component of this pathological adaptation [37, 38]. Also, hepatic lipid accumulation is tightly
regulated by the nuclear receptor PPARα. Beneficial effects of HO-1-induction on hepatic lipid
accumulation have been reported before [39]; however, we show here for the first time that HO-
1 induction can alter hepatic-metabolic signaling in an environment of HFr. SIRT1-dependence
of this protective effect of HO-induction is the second key finding of the study. Our results sug-
gest that fructose-mediated alteration in cellular redox and subsequent attenuation of SIRT1
mediate, at least in part, activation of the lipogenic pathways. SIRT1 is a crucial NAD-dependent
deacetylase that suppresses gene expression via decreasing chromatin acetylation. This, in turn,
increases chromatin condensation and reduces access of transcription factors to the promoter
region of the affected gene. SIRT1 has been reported to suppress pro-inflammatory and pro-
fibrotic pathways, and also regulates genes involved in energy metabolism [30, 31, 54]. Fructose-
induced activation of pro-lipogenic pathways is accompanied by attenuation of SIRT1. Impor-
tantly, reversal of these pro-lipogenic pathways by HO-1 is associated with SIRT1 rescue. SIRT1
plasmid and silencing RNA experiments strongly suggest that beneficial effects of HO-1 are
SIRT1-dependent. This, however, does not exclude the possibility of SIRT1-independent
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component of the effects of HO-1. But overall, our in vitro results indicate that at least part of the
protective actions the HO system on the metabolic pathways in hepatocytes is via SIRT1-rescue.
Importantly, SIRT1 up-regulates these metabolic regulators in multiple settings [30, 31, 54]. Pos-
sible downstream targets for the HO1-SIRT1 module could include AMPK and PPARα. With
regards to these proteins, p-AMPK/AMPK and PPARα are known to modulate the hepatic meta-
bolic pathways [37, 54] and their activation leads to reduction in hepatic glucose output, suppres-
sion of pro-lipogenic pathways and improvement in liver function.
A murine model of diet-induced hepatic steatosis and fibrosis confirms our in vitro findings.
Third key finding of the study highlights the hepato-protective effect of HO-1 in mice fed a
HFr diet. CoPP treated mice showed significant improvement in hepatic steatosis, fibrosis and
metabolic balance. Hepatic FAS levels were down regulated while insulin signaling improved,
in mice with increased levels of HO-1 induction. Although HFr mediated NAFLD is well estab-
lished, the precise molecular mechanisms remain incompletely understood. Up-regulation of
HO-1 attenuate adiposity in mice fed high-fat diet by reprogramming adipocyte phenotype to
functional health adipocyte [55]. HO-1 induction reversed fructose-mediated increase in oxi-
dants, isoprostane production and adipocyte dysfunction [56]. HO-1 gene targeting either adi-
pocytes or vascular system attenuates adiposity, ROS and vascular dysfunction in mice fed a
high-fat diet [55,57]. Our results, showing high redox potential in hepatic tissues of mice fed
HFr, are in line with these reports and lead us to believe that ROS-dependent pathways are cen-
tral to the pathophysiology of NAFLD [58]. ROS-induced SIRT1 suppression is one of these
candidate pathways. By interfering with this NAD-dependent deacetylase, high oxidative stress
alters cellular metabolic balance and HO-1 system is the first line of defense against such inju-
ries. We demonstrate in this study that induction of HO-1 leads to a reduction in lipid accumu-
lation and FFA, a decrease in blood glucose levels and a decrease in ROS and inflammation in
hepatocytes, a major cause of insulin resistance. It is important to note that our findings are in
contrast with the recent work by Jais et al. The authors showed that liver-specific KO of HO-1
decreases hepatic lipid accumulation and that overexpression of HO-1 in hepatocytes results in
insulin resistance. At this time we are not fully able to explain the dissimilarities in our results;
however, certain differences in the experimental design do stand out. First, Jais et al used a
model of high-fat diet to induce hepatic steatosis whereas HFr was used in ours. It could be
that insulin resistance and hepatic steatosis brought on by these diets engage distinct cellular
defense mechanisms and adaptive responses. Additionally, activation of compensatory
responses during HO-1 KO, such as HO-2, may contribute to the observed differences in our
findings. Secondly, Jais et al used adenoviral constructs to show that acute overexpression of
HO-1 (7 days) in hepatocytes results in insulin resistance. We have used a model of chronic up
regulation of HO-1 and temporal changes in the role of this system may occur during meta-
bolic homeostasis; further studies are needed to fully resolve this issue.
ROS and oxidative stress are the major causes of liver damage and are involved in the develop-
ment of hepatic fibrosis by inducing hepatic stellate cells proliferation and collagen synthesis [26].
HSCs activation is regulated by cytokines and ROS released by damaged hepatocytes [27, 28].
Importantly, progression of hepatic steatosis to fibrosis is reliant upon the activation of inflamma-
tory, fibrotic and tissue remodeling pathways including, matrix metalloproteinases, that in turn
are suppressed by the NAD-dependent deacetylases superfamily [59, 60]. ROS also enhances
TGF1β, inducing hepatocellular inflammation and fibrogenic activity [28]. In line of this evi-
dence, our results showed that HO-1 induction attenuated the hepatic fibrosis probably by rescu-
ing cellular SIRT1 and by attenuating inflammation in a model of diet-induced hepatic steatosis.
These results allude to a HO-1-SIRT1 axis where the antioxidant properties of HO-1 preserve the
functional integrity of SIRT1, which, in turn, works with HO-1 to attenuate the development of
steatohepatitis and progression to hepatic fibrosis while restoring metabolic balance.
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Hepatic steatosis also increases the risk for CVD [13, 15] leading to endothelial dysfunction,
atherosclerosis and hypertension [14, 61, 62]. Non-alcoholic fatty liver might contribute in the
pathogenesis of CVD through the systemic release of inflammatory and oxidative-stress media-
tors or through the contribution of hepatic steatosis to insulin resistance and atherogenic dysli-
pidemia. Our results showed that HO-1-SIRT1 axis salvaged endothelial dysfunction by
modulating signaling and survival pathways to improve NAFLD-induced CVDs. Increased lev-
els of HO-1 are associated with an increase in peNOS, and NO bioavailability [63, 64]. Also an
increase in AMPK signaling is considered an important metabolic response key to the attenua-
tion of ROS-mediated endothelial dysfunction, since pAMPK utilizes eNOS as a substrate and
enhances the levels of peNOS [64, 65]. In agreement with these reports, our results demon-
strate that the HO-1-SIRT1 axis increases the level of peNOS and pAMPK to ameliorate vascu-
lar dysfunction. Taken together, these observations solidify our notion that a HFr diet affects
inflammatory and redox pathways in both, liver and vascular tissues and that activation of the
HO-1-SIRT1 module has the ability to counteract these changes. This insight may prove to
have profound therapeutic implications for treatment of nonobese type 2 diabetics who have
already attempted lifestyle modification with diet and exercise since directly targeting NAFLD
could be a particularly high yield intervention for them, decreasing glycemia and risk of
adverse cardiovascular events.
In conclusion (Fig 9), this study demonstrates that HO-1 induction in the liver reduced
fructose-induced hepatic lipid deposition, prevented the development of hepatic fibrosis and
abated NAFLD-associated metabolic and vascular imbalance; effects that are mediated by
Fig 9. Schematic demonstrating HO-1 induction attenuates fructose-induced hepatic lipid deposition,
prevent the development of hepatic fibrosis and abate NAFLD-associated vascular dysfunction;
effects that are mediated by activation of the SIRT1 gene expression.
doi:10.1371/journal.pone.0128648.g009
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activation of the SIRT1 gene expression. It is evident that the SIRT family of genes is key play-
ers in redox biology. Further studies are needed, however, to fully elucidate the HO-1-SIRT1
interactions in intact animals. Hepatocyte-specific SIRT1 KOmice will further our understand-
ing of these interactions. We believe that elucidating these interactions will lead to the develop-
ment of new biomarkers and therapeutic strategies to fight hepatic dysfunction associated with
NAFLD.
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